Table 3 Multivariate Cox proportional hazard model for overall survival.

From: Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study

Variables

HR (95% CI)

P value

OS (≤12 months)

    - HCT

Ref

<0.01

    - JAKi

0.14 (0.07–0.28)

 

OS (>12 months)

    - HCT

Ref

0.03

    - JAKi

1.98 (1.08–3.61)

 

Diagnosis

    - PMF

Ref

<0.03

    - Post-ET/PV MF

0.65 (0.45–0.94)

 

Age at initial visit

1.02 (1.00–1.04)

0.25

DIPSSa

    - Intermediate-1

Ref

 

    - Intermediate-2

1.63 (1.07–2.48)

0.03

    - High

2.43 (1.25–4.70)

0.01

Transfusion-requiring anemia

    - No

Ref

0.36

    - Yes

1.23 (0.79–1.90)

 

Thrombocytopenia, platelet count < 100 × 109/L

    - No

Ref

0.04

    - Yes

1.55 (1.02–2.36)

 

JAK2

    - Wild type

Ref

0.88

    - Mutated

0.97 (0.66–1.44)

 

Unfavorable cytogenetic abnormalityb

    - Absent

Ref

0.52

    - Present

1.18 (0.72–1.93)

 
  1. HR Hazard ratio, CI Confidence interval, Ref Reference, OS Overall survival, MF myelofibrosis, PMF primary myelofibrosis, ET essential thrombocythemia, PV polycythemia vera, DIPSS dynamic international prognostic scoring system, Int intermediate.
  2. aAt the time of initiation of JAKi or HCT.
  3. b+8, -7/7q-, i(17q), inv(3), -5/5q, 12p-, or 11q23 rearrangements.
Back to article page